Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical trials in developing countries: scientific and ethical issues

D M Studdert1, T A Brennan

  • 1Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA. studdert@rand.org

The Medical Journal of Australia
|December 23, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.

Journal of clinical pharmacy and therapeutics·2016
Same author

Can law improve prevention and treatment of cancer?

Public health·2011
Same author

Relationship between complaints and quality of care in New Zealand: a descriptive analysis of complainants and non-complainants following adverse events.

Quality & safety in health care·2006
Same author

Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. 1991.

Quality & safety in health care·2004
Same author

Managing care in the new era of "systems-think": the implications for managed care organizational liability and patient safety.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2002
Same author

Intention to discontinue care among primary care patients: influence of physician behavior and process of care.

Journal of general internal medicine·2001

Intensive zidovudine treatment significantly reduces mother-to-child HIV transmission. Ethical debates arise over using placebos in trials for developing countries versus established regimens in developed nations.

Area of Science:

  • Medical Ethics
  • Infectious Disease Epidemiology
  • Global Health

Background:

  • The 1994 discovery highlighted zidovudine's efficacy in preventing perinatal human immunodeficiency virus (HIV) transmission.
  • This intensive treatment has become standard practice in developed nations for preventing mother-to-child HIV transmission.
  • Trials in developing countries explore less intensive, cost-effective regimens, often utilizing placebo controls.

Purpose of the Study:

  • To examine the ethical considerations surrounding the use of placebo controls in human immunodeficiency virus (HIV) prevention trials in developing countries.
  • To address the controversy regarding differing ethical standards in developed versus developing nations concerning HIV treatment access and research.

Main Methods:

  • Review of ethical guidelines and trial methodologies for preventing perinatal HIV transmission.
Keywords:
Biomedical and Behavioral Research

Related Experiment Videos

  • Analysis of the implications of placebo-controlled trials versus active-controlled or observational studies.
  • Examination of the impact of healthcare resource disparities on ethical research practices.

    • Main Results:

    • Widespread adoption of intensive zidovudine regimens in developed countries contrasts with trials using placebos in developing nations.
    • Significant controversy exists regarding the ethical justification for placebo use when effective treatments are available elsewhere.
    • Disparities in healthcare needs and budgets raise questions about universal ethical standards in global health research.

    Conclusions:

    • The use of placebo controls in human immunodeficiency virus (HIV) prevention trials in developing countries remains ethically contentious.
    • Balancing the need for rigorous scientific evidence with equitable access to care is a critical challenge in global health.
    • Further discussion is needed to establish ethical frameworks that accommodate diverse healthcare contexts while upholding patient welfare.